REGENXBIO Inc

Insider selling: REGENXBIO’s Chief Medical Officer sells 15,309 shares at $11.02 in a Rule 10b5‑1 plan—steady, rule‑based moves that may signal confidence but also prompt investor vigilance for future volatility.

Insider sale of 5,124 shares by REGENXBIO’s CMO shows disciplined liquidity management, not a bearish signal, amid rising fundamentals and upcoming Q2 trial data.

Insider sale of 4,700 REGENXBIO shares amid FDA pause: tax‑driven move, not a confidence signal – what it means for investors and stock outlook.

Insider buying spurs confidence in REGENXBIO amid FDA holds—learn why execs are buying shares and what it signals for investors.